These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 11438565)

  • 1. Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses.
    Griffith TS; Kawakita M; Tian J; Ritchey J; Tartaglia J; Sehgal I; Thompson TC; Zhao W; Ratliff TL
    J Natl Cancer Inst; 2001 Jul; 93(13):998-1007. PubMed ID: 11438565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth.
    Kawakita M; Rao GS; Ritchey JK; Ornstein DK; Hudson MA; Tartaglia J; Paoletti E; Humphrey PA; Harmon TJ; Ratliff TL
    J Natl Cancer Inst; 1997 Mar; 89(6):428-36. PubMed ID: 9091644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral vector delivery in solid-state vehicles: gene expression in a murine prostate cancer model.
    Siemens DR; Austin JC; Hedican SP; Tartaglia J; Ratliff TL
    J Natl Cancer Inst; 2000 Mar; 92(5):403-12. PubMed ID: 10699070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors.
    Elzey BD; Siemens DR; Ratliff TL; Lubaroff DM
    Int J Cancer; 2001 Dec; 94(6):842-9. PubMed ID: 11745487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy.
    Grant JF; Iwasawa T; Sinn HW; Siemens DR; Griffith TS; Takacs EB; Ratliff TL
    Int J Cancer; 2006 Dec; 119(11):2632-41. PubMed ID: 16991124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of whole-cell tumor preparations infected with the ALVAC viral vector.
    Ghose A; Iakhnina E; Spaner D; Tartaglia J; Berinstein NL
    Hum Gene Ther; 2000 Jun; 11(9):1289-301. PubMed ID: 10890739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity.
    Puisieux I; Odin L; Poujol D; Moingeon P; Tartaglia J; Cox W; Favrot M
    Hum Gene Ther; 1998 Nov; 9(17):2481-92. PubMed ID: 9853515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53.
    Odin L; Favrot M; Poujol D; Michot JP; Moingeon P; Tartaglia J; Puisieux I
    Cancer Gene Ther; 2001 Feb; 8(2):87-98. PubMed ID: 11263530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Poxvirus vectors for gene transfer].
    Kawakita M; Yoshida O; Ratliff TL
    Hinyokika Kiyo; 1997 Nov; 43(11):835-8. PubMed ID: 9436032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor protection by IL-7 secreting whole cell vaccine is merely mediated by NK1.1-positive cells.
    Schroten C; Scheffer R; Boon L; de Ridder CM; Bangma CH; Kraaij R
    J Immunother; 2012; 35(2):125-30. PubMed ID: 22306900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.
    Hodge JW; McLaughlin JP; Kantor JA; Schlom J
    Vaccine; 1997; 15(6-7):759-68. PubMed ID: 9178479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.
    Kozar K; Kamiński R; Switaj T; Ołdak T; Machaj E; Wysocki PJ; Mackiewicz A; Lasek W; Jakóbisiak M; Gołab J
    Clin Cancer Res; 2003 Aug; 9(8):3124-33. PubMed ID: 12912964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response.
    Ullenhag GJ; Frödin JE; Mosolits S; Kiaii S; Hassan M; Bonnet MC; Moingeon P; Mellstedt H; Rabbani H
    Clin Cancer Res; 2003 Jul; 9(7):2447-56. PubMed ID: 12855617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
    Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
    Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver CD4-CD8- NK1.1+ TCR alpha beta intermediate cells increase during experimental malaria infection and are able to exhibit inhibitory activity against the parasite liver stage in vitro.
    Pied S; Roland J; Louise A; Voegtle D; Soulard V; Mazier D; Cazenave PA
    J Immunol; 2000 Feb; 164(3):1463-9. PubMed ID: 10640763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma.
    Wong RJ; Patel SG; Kim S; DeMatteo RP; Malhotra S; Bennett JJ; St-Louis M; Shah JP; Johnson PA; Fong Y
    Hum Gene Ther; 2001 Feb; 12(3):253-65. PubMed ID: 11177562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse NK1.1+ cytotoxic T cells can be generated by IL-2 exposure from lymphocytes which express an intermediate level of T cell receptor.
    Ikarashi Y; Maruoka H; Shinohara K; Sugimura T; Terada M; Wakasugi H
    Immunol Lett; 1998 Apr; 61(2-3):165-73. PubMed ID: 9657270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice.
    Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Wu MS; Izawa K; Hamada H; Asano S
    Cancer Gene Ther; 1998; 5(1):29-37. PubMed ID: 9476964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium.
    Yuhua L; Kunyuan G; Hui C; Yongmei X; Chaoyang S; Xun T; Daming R
    Int J Cancer; 2001 Nov; 94(3):438-43. PubMed ID: 11745427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.